Investor Presentaiton
Investor presentation
ADA 2019
Slide 11
SUSTAIN FORTE will evaluate high-dose semaglutide in type
2 diabetes and is expected to conclude by end of 2020
Randomised:
964 patients
with type 2
diabetes
SUSTAIN FORTE trial design
Semaglutide 2.0 mg
Semaglutide 1.0 mg
40 weeks
Trial objective
To establish the effect of semaglutide sc 2.0 mg QW vs.
semaglutide 1.0 mg QW on glycaemic control in patients with
type 2 diabetes on a background of metformin with or
without SU treatment
Key SUSTAIN FORTE trial inclusion criteria
People with type 2 diabetes from 10 countries
•
HbA1c 8-10%
•
Stable dose of metformin +/- SU
High-dose semaglutide
Supports individualised treatment
Offers a simple treatment regimen for intensification
Trial initiation: Q2 2019
sc: subcutaneous; QW: once-weekly; SU: sulphonylurea
novo nordiskView entire presentation